Key result
JAK2 V617F promotes unconventional autophagosome-lysosome TpoR secretion, while CALR mutations restrict it to Golgi-dependent pathways.
Why the study?
The mechanisms of thrombopoietin receptor secretion and its modulation by distinct driver mutations in myeloproliferative neoplasm were unclear, particularly regarding lysosomal localization indicating degradation or secretion.
The study demonstrates an unconventional autophagosome-lysosome mediated secretion pathway for the thrombopoietin receptor that is differentially modulated by myeloproliferative neoplasm driver mutations.
May differentiate autophagy-targeted responses in JAK2- vs CALR-mutated MPNs; leaves open whether pathway modulation offers mutation-specific benefit.
The maintenance of the haematopoietic stem cells and the production of platelets thereof is acutely dependent upon the thrombopoietin receptor (TpoR). TpoR dimerizes in the presence of its ligand thrombopoietin leading to the activation of downstream JAK2-STAT signalling. Alternatively, the receptor dimerizes in the presence of activating mutations of JAK2 (JAK2 V617F), calreticulin or TpoR leading to myeloproliferation. These effects are dependent upon the surface expression of the receptor. TpoR is secreted through the Golgi-dependent pathway. Although, an unconventional autophagosome-lysosome mediated traffic has been postulated; questions remained whether the observed lysosomal localization was indicative of degradation or secretion. We fused the pH-sensitive FRET pair of TOLLES-YPet with TpoR (SRAI-TpoR) that showed FRET quenching at low pH environment of lysosomes. Using this construct, we demonstrated the presence of quenched SRAI-TpoR on the cell surface indicating that TpoR could indeed be secreted through low pH compartments. We further demonstrated that the lysosome-autophagosome-mediated secretion of TpoR was promoted by JAK2 V617F mutation, partially utilized by TpoR W515L but abrogated by calreticulin mutations. Finally, we showed that the lysosome-autophagosome mediated secretion was dependent upon Rab1A. Our study conclusively showed the unconventional traffic of TpoR and its modulation by the driver mutations causing myeloproliferation.
No takes yet. Share an insight, caveat, or question.
Shrivastva et al. (2025) studied Myeloproliferative neoplasm. MPN driver mutations (JAK2 V617F, TpoR W515L, CALR mutations) vs. Wild-type (JAK2 WT, TpoR WT) was evaluated on TpoR subcellular localization and secretion pathway. The JAK2 V617F mutation promotes unconventional autophagosome-lysosome-mediated secretion of the thrombopoietin receptor, whereas CALR mutations block this pathway and restrict the receptor to Golgi-dependent secretion.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: